Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
173
datasets available to search
ShareScore release 0.9.0
Dataset results
173 results for “Malignant pleural mesothelioma;”
Differential gene expression profiles of side population and non-side population cells of malignant pleural mesothelioma
GEO Series GSE33734. Homo sapiens. 4 samples. Type: Expression profiling by array.
Real-time quantitative PCR analysis of human malignant pleural mesothelioma tissue specimens
GEO Series GSE54394. Homo sapiens. 15 samples. Type: Expression profiling by RT-PCR.
Dataset related to article "Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience."
<p>INTRODUCTION:</p> <p>We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM) after lung-sparing surgery with pleurectomy and decortication.</p> <p>MATERIALS AND METHODS:</p> <p>Patients affected by MPM who had undergone pleurectomy and decortication and adjuvant radiotherapy with VMAT were included. The endpoints of the present analysis were local control, progression-free survival, and overall survival. Assessment of the variables affecting survival was performed using univariate and multivariate Cox proportional hazard models.</p> <p>RESULTS:</p> <p>A total of 49 patients were included in the present study. Of the 49 patients, 96% had been treated with a trimodality approach. Radiotherapy was delivered to a median dose of 44 Gy in 22 fractions (range, 22-59.4 Gy). The treatment was well tolerated, with just 2 grade 3 acute toxicities, 1 grade 5, and 2 grade 4 toxicities recorded during the follow-up period. The median follow-up period was 27.4 months. The local control rate at 12, 24, and 36 months was 75.2%, 67.4%, and 56.5%, respectively. The median progression-free survival was 14.9 months (95% confidence interval [CI], 7.5-25.2). The median overall survival was 21.5 months (95% CI, 15.3-37.1). On multivariate analysis, the administration of carboplatin- instead of cisplatin-based chemotherapy (hazard ratio, 2.97; 95% CI, 1.22-7.26; P = .017) and R2 resection (hazard ratio, 1.95; 95% CI, 1.27-2.99; P = .002) showed a negative correlation with overall survival. On univariate analysis, the percentage of the heart receiving >20 Gy and >30 was associated with the occurrence of late pneumonitis (P = .018 and P = .077).</p> <p>CONCLUSION:</p> <p>VMAT is feasible in the setting of MPM after lung-sparing surgery. The toxicity rates were reduced with this technique compared with historical data of older techniques. Local and distant failure remain a major issue to be addressed in future trials.</p>
Dataset related to article "Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas's Experience"
<p>This record contains raw data related to article “Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas's Experience"</p> <p><strong>Background: </strong> We analysed a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent extended Pleurectomy/Decortication (eP/D) in a centre with a high level of thoracic surgery experience (IRCCS Humanitas Research Hospital) to explore postoperative morbidity and mortality, pattern of recurrence and survival.</p> <p><strong>Methods: </strong> A retrospective analysis was performed on MPM patients underwent eP/D in our centre from 2010 to 2021. All patients were identified from our departmental database. Postoperative complications were scored according to Clavien-Dindo criteria. Survival analysis was performed by the Kaplan-Meier methods and Cox multivariable analysis.</p> <p><strong>Results: </strong> Eighty-five patients underwent extended pleurectomy decortication (eP/D) during study period. Macroscopical residual disease (R2) was reported in one case. A neoadjuvant chemotherapy regiment was administrated in 88% of the surgical cohort. A complete trimodality treatment including induction with platinum agents and pemetrexed, radical cytoreductive surgery and volumetric modulated arc therapy technology (VMAT) could be administered in 63 patients (74%). Postoperative morbidity rate was 54.11%, major complications (defined as Clavien-Dindo ≥ 3) were reported in 11 patients (12.9%). Thirty-day mortality and 90-day mortality were, respectively, 2.35% and 3.53%. Median disease-free and overall survival were, respectively, 13.7 and 25.5 months. The occurrence of major complications (Clavien-Dindo ≥ 3), operative time, pT3-T4, pathological node involvement (pN+) were prognostic factors associated with worse survival.</p> <p><strong>Conclusions: </strong> In our experience, eP/D is a well-tolerated procedure with acceptable mortality and morbidity, allowing for the administration of trimodality regimens in most patients. eP/D offered in a multimodality treatment setting have satisfactory long term oncological results. To obtain best oncological results the goal of surgery should be macroscopic complete resection in carefully selected patients (clinical N0).</p>
Dataset related to article "Single-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma "
<p>This record contains raw data related to article “Single-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma"</p> <p><strong>Objectives: </strong> We examined a series of malignant pleural mesothelioma (MPM) patients who consecutively underwent surgery in our institution during the last 20 years. Across this period, we changed our surgical approach to MPM, adopting extended pleurectomy and decortication (eP/D) instead of extrapleural pneumonectomy (EPP). In this study, we compare the perioperative outcomes and long-term survival of patients who underwent EPP vs. eP/D.</p> <p><strong>Methods: </strong> A retrospective analysis was carried out of all the MPM patients identified from our departmental database who underwent EPP or P/D from 2000 to 2021. Clavien-Dindo criteria was adopted to score postoperative complications, while Kaplan-Meier methods and a Cox multivariable analysis were used to perform the survival analysis.</p> <p><strong>Results: </strong> Of 163 patients, 78 (48%) underwent EPP and 85 (52%) eP/D. Induction chemotherapy was significantly administrated more often in the eP/D group (88% vs. 51%). Complete trimodality treatment including induction chemotherapy, radical surgery, and adjuvant radiotherapy was administered in 74% of the eP/D group versus 32% of the EPP group (<em>p</em> &lt; 0.001). The postoperative morbidity rate was higher in the eP/D group (54%) compared to the EPP group (36%) (<em>p</em> = 0.02); no statistically significant differences were identified concerning major complications (EPP 43% vs. eP/D 24%, <em>p</em> = 0.08). No statistical differences were identified in 30-day mortality, 90-day mortality, median disease-free, and overall survival statistics between the two groups. The Cox multivariable analysis confirmed no induction chemotherapy (HR, 0.5; <em>p</em> = 0.002), RDW (HR, 1.08; <em>p</em> = 0.02), and the presence of pathological nodal disease (HR, 1.99; <em>p</em> = 0.001) as factors associated with worse survival in the entire series.</p> <p><strong>Conclusions: </strong> Our data support that eP/D is a well-tolerated procedure allowing the implementation of a trimodality strategy (induction chemotherapy, surgery, and radiotherapy) in most MPM patients. When eP/D is offered in this setting, the oncological results are comparable to EPP. To obtain the best oncological results, the goal of surgical resection should be macroscopic complete resection (R0) in carefully selected patients (clinical N0).</p>
Dataset related to article "Important functional role of the protein Osteopontin in the progression of malignant pleural mesothelioma"
<p>This record contains raw data related to article “Important functional role of the protein Osteopontin in the progression of malignant pleural mesothelioma"</p> <p>Background: Malignant Pleural Mesothelioma (MPM) is an aggressive cancer of the mesothelial lining associated with exposure to airborne non-degradable asbestos fibers. Its poor response to currently available treatments prompted us to explore the biological mechanisms involved in its progression. MPM is characterized by chronic non-resolving inflammation. in this study we investigated which inflammatory mediators are mostly expressed in biological tumour samples from MPM patients.<br> Methods: Expression and quantification of Osteopontin (OPN) was detected in tumour and plasma samples of MPM patients by mRNA, immunohistochemistry and ELISA. The functional role of OPN was investigated in mouse MPM cell lines in vivo using an orthotopic syngeneic mouse model.<br> Results: In patients with MPM, the protein OPN was significantly more expressed in tumours than in normal pleural tissues and predominantly produced by mesothelioma cells; plasma levels were elevated in patients and associated with poor prognosis. However, modulation of OPN levels was not significantly different in a series of 18 MPM patients receiving immunotherapy with durvalumab alone or with pembrolizumab in combination with chemotherapy, some of whom achieved a partial clinical response. Two established murine mesothelioma cell lines: AB1 and AB22 of sarcomatoid and epithelioid histology, respectively, spontaneously produced high levels of OPN. Silencing of the OPN gene (Spp1) dramatically inhibited tumour growth in vivo in an orthotopic model, indicating that OPN has an important promoting role in the proliferation of MPM cells. Treatment of mice with anti-CD44 mAb, blocking a major OPN receptor, significantly reduced tumour growth in vivo.<br> Conclusions: These results demonstrate that OPN is an endogenous growth factor for mesothelial cells and inhibition of its signaling may be helpful to restrain tumour progression in vivo. These findings have translational potential to improve the therapeutic response of human MPM</p>
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT01353482. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Affymetrix OncoScan FFPE Microarray data for Malignant Pleural Mesothelioma Samples
GEO Series GSE109305. Homo sapiens. 4 samples. Type: Genome variation profiling by SNP array.
Identification of novel markers for malignant pleural mesothelioma diagnosis
GEO Series GSE17310. Homo sapiens. 54 samples. Type: Expression profiling by array.
Dataset related to article "In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma."
<p>OBJECTIVES:</p> <p>In-vivo characterization of malignant pleural mesothelioma (MPM) with C-methionine PET/computed tomography (MET PET).</p> <p>METHODS:</p> <p>Between September 2014 and February 2016, 30 consecutive patients with clinical suspicion of MPM were prospectively recruited. The study was approved and registered at www.clinicaltrials.gov (<a href="http://clinicaltrials.gov/show/NCT02519049">NCT02519049</a>). Patients were evaluated at baseline with MET PET (experimental) and fluorine-18 fluorodeoxyglucose PET/computed tomography (FDG PET) (standard). Principal parameters analyzed were SUVmax, SUVmean, metabolic tumor volume (MTV), and metabolic tumor burden (MTB  =&thinsp;MTV ×SUVmean). The reference standard for diagnostic performance was based on histology.</p> <p>RESULTS:</p> <p>The presence of malignancy was confirmed in 29/30 patients: 23 (76.6%) with MPM (20 epithelioid, two biphasic, and one sarcomatoid), five (16.6%) with adenocarcinoma of the lung, and one (3.3%) with an undifferentiated carcinoma. In one case, diagnosis was benign pleural inflammation. All tumors showed increased uptake of C-methionine: median SUVmax, SUVmean, MTV, and MTB were, respectively, 5.70 [95% confidence interval (CI): 4.51-6.79], 3.15 (95% CI: 2.71-3.40), 33.85 (95% CI: 14.08-66.64), and 105.25 (95% CI: 41.77-215.25). Pathology data revealed MTV and MTB to be significantly higher in nonepithelioid histology (P < 0.05). The other parameters showed a homogeneous distribution across the tumor types. Overall, MET PET identified 49 lymph nodes, compared with 34 nodes on FDG PET, demonstrating a sensitivity of 91% (95% CI: 80-96%), a positive predictive value of 92% (95% CI: 82- 97%), and an accuracy of 85% (P = 0.0042).</p> <p>CONCLUSIONS:</p> <p>MET PET is able to characterize MPM lesions regardless of histology. This technique shows higher sensitivity than FDG PET for the identification of secondary lymph nodes.</p>
Dataset related to article "Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma"
<p>This record contains raw data related to article "Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma"</p><p><strong>Background: </strong>Malignant Pleural Mesothelioma (MPM) is an aggressive cancer of the mesothelial lining associated with exposure to airborne non-degradable asbestos fibers. Its poor response to currently available treatments prompted us to explore the biological mechanisms involved in its progression. MPM is characterized by chronic non-resolving inflammation; in this study we investigated which inflammatory mediators are mostly expressed in biological tumor samples from MPM patients, with a focus on inflammatory cytokines, chemokines and matrix components.</p><p><strong>Methods: </strong>Expression and quantification of Osteopontin (OPN) was detected in tumor and plasma samples of MPM patients by mRNA, immunohistochemistry and ELISA. The functional role of OPN was investigated in mouse MPM cell lines <i>in vivo</i> using an orthotopic syngeneic mouse model.</p><p><strong>Results: </strong>In patients with MPM, the protein OPN was significantly more expressed in tumors than in normal pleural tissues and predominantly produced by mesothelioma cells; plasma levels were elevated in patients and associated with poor prognosis. However, modulation of OPN levels was not significantly different in a series of 18 MPM patients receiving immunotherapy with durvalumab alone or with pembrolizumab in combination with chemotherapy, some of whom achieved a partial clinical response. Two established murine mesothelioma cell lines: AB1 and AB22 of sarcomatoid and epithelioid histology, respectively, spontaneously produced high levels of OPN. Silencing of the OPN gene (<i>Spp1</i>) dramatically inhibited tumor growth <i>in vivo</i> in an orthotopic model, indicating that OPN has an important promoting role in the proliferation of MPM cells. Treatment of mice with anti-CD44 mAb, blocking a major OPN receptor, significantly reduced tumor growth <i>in vivo</i>.</p><p><strong>Conclusion: </strong>These results demonstrate that OPN is an endogenous growth factor for mesothelial cells and inhibition of its signaling may be helpful to restrain tumor progression <i>in vivo</i>. These findings have translational potential to improve the therapeutic response of human MPM.</p>
MesoHET (Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma)
GEO Series GSE175769. Homo sapiens. 10 samples. Type: Methylation profiling by genome tiling array.
Expression data from in vitro healthy cells and malignant pleural mesothelioma cell lines infected by oncolytic attenuated measles virus or treated by exogenous type I interferon
GEO Series GSE117668. Homo sapiens. 48 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.